NasdaqGS:ALNYBiotechs
Alnylam Data Update Highlights RNAi Potential And Undervalued Share Price
Alnylam Pharmaceuticals has reported new clinical and real world data on its RNAi therapy vutrisiran in ATTR-CM, highlighting durable benefits in quality of life and reductions in advanced disease progression and mortality.
The company has also shared pooled Phase 2 safety data for zilebesiran that supports its move into a global Phase 3 trial in hypertension and cardiovascular risk reduction.
For investors tracking NasdaqGS:ALNY, this update centers on the company’s core RNAi franchise and...